| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ART.27758 |
| P698 | PubMed publication ID | 20862678 |
| P50 | author | Lars Klareskog | Q5912759 |
| Johan Askling | Q89669829 | ||
| Saedis Saevarsdottir | Q90603200 | ||
| Sara Wedrén | Q114337587 | ||
| Staffan Lindblad | Q114341727 | ||
| Maria Seddighzadeh | Q114341730 | ||
| Annmarie Wesley | Q114402425 | ||
| Lars Alfredsson | Q30349390 | ||
| P2093 | author name string | Camilla Bengtsson | |
| P2860 | cites work | Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group. | Q52919247 |
| Rheumatoid arthritis | Q57349151 | ||
| Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register | Q57751361 | ||
| A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis | Q57788757 | ||
| Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial | Q58234944 | ||
| Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4 | Q24538382 | ||
| Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years | Q24674079 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations | Q33369384 | ||
| A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis | Q33982255 | ||
| Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati | Q34662758 | ||
| Cigarette smoking and rheumatoid arthritis severity | Q35547371 | ||
| HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments | Q35547815 | ||
| Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression | Q35555003 | ||
| Swedish registers to examine drug safety and clinical issues in RA. | Q35637262 | ||
| Sex: a major predictor of remission in early rheumatoid arthritis? | Q35638333 | ||
| Cigarette smoking and radiographic progression in rheumatoid arthritis | Q35953570 | ||
| Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis? | Q37000103 | ||
| Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis | Q37000109 | ||
| The BeSt story: on strategy trials in rheumatoid arthritis | Q37422987 | ||
| Recent progress in rheumatoid arthritis genetics: one step towards improved patient care | Q37443734 | ||
| Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies | Q42653404 | ||
| A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination | Q42676934 | ||
| Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers | Q43201741 | ||
| Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment | Q45915302 | ||
| The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept | Q46114766 | ||
| Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis | Q47784100 | ||
| High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. | Q51824341 | ||
| P433 | issue | 1 | |
| P921 | main subject | immunology | Q101929 |
| patient | Q181600 | ||
| epidemiology | Q133805 | ||
| rheumatoid arthritis | Q187255 | ||
| rheumatology | Q327657 | ||
| methotrexate | Q422232 | ||
| P304 | page(s) | 26-36 | |
| P577 | publication date | 2010-12-28 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatolog | |
| P478 | volume | 63 |
| Q37470261 | A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study |
| Q35557430 | A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine |
| Q58102049 | Acceptable quality of life and low disease activity achievable among transition phase patients with rheumatic disease |
| Q30656861 | Alcohol consumption is associated with lower self-reported disease activity and better health-related quality of life in female rheumatoid arthritis patients in Sweden: data from BARFOT, a multicenter study on early RA |
| Q61958824 | Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease? |
| Q33893385 | Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance |
| Q38881099 | Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up |
| Q42608056 | Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort |
| Q26783657 | Biologic efficacy optimization--a step towards personalized medicine |
| Q30234303 | Biologics registers in RA: methodological aspects, current role and future applications |
| Q56828560 | Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response |
| Q38813397 | Cardiovascular risk in patients with rheumatoid arthritis |
| Q83985772 | Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease |
| Q37013908 | Cigarette smoking and musculoskeletal disorders |
| Q55512246 | Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. |
| Q38286234 | Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases |
| Q30936806 | Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers |
| Q50480103 | Creating a culture of health: evolving healthcare systems and patient engagement. |
| Q35891851 | Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial |
| Q37728616 | DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis |
| Q36633164 | Dendritic cells provide a potential link between smoking and inflammation in rheumatoid arthritis |
| Q60304759 | Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis |
| Q40984627 | Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden |
| Q51647437 | Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study. |
| Q36853631 | Effect of Exposure to Tobacco Smoke on Response to Anti-Tumor Necrosis Factor-Alpha Treatment in Patients with Rheumatoid Arthritis |
| Q40687578 | Efficacy of a Rheumatoid Arthritis-Specific Smoking Cessation Program: A Randomized Controlled Pilot Trial |
| Q36110733 | Environmental and gene-environment interactions and risk of rheumatoid arthritis |
| Q37883018 | Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. |
| Q88886408 | Expert recommendations on the psychological needs of patients with rheumatoid arthritis |
| Q34374946 | Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis |
| Q48724904 | Higher body mass index and anti-drug antibodies predict the discontinuation of anti-TNF agents in Korean patients with axial spondyloarthritis |
| Q64927637 | How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. |
| Q48365860 | Human microbiome, infections, and rheumatic disease |
| Q36056195 | Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response. |
| Q36183760 | Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment |
| Q38631840 | IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. |
| Q37191106 | Impact of managed care health insurance system for indigent patients with rheumatoid arthritis in Puerto Rico. |
| Q40251018 | Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry |
| Q41456495 | Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis. |
| Q90049984 | Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study |
| Q41621762 | Is Male Rheumatoid Arthritis an Occupational Disease? A Review |
| Q38958301 | Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study |
| Q41927788 | Low levels of antibodies against common viruses associate with anti-citrullinated protein antibody-positive rheumatoid arthritis; implications for disease aetiology |
| Q38676903 | Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal? |
| Q39210337 | Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches |
| Q36907694 | Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort |
| Q40706877 | Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. |
| Q90236306 | MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis |
| Q26739010 | Microbiota and chronic inflammatory arthritis: an interwoven link |
| Q26829955 | My treatment approach to rheumatoid arthritis |
| Q37587409 | Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis |
| Q34559803 | Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? |
| Q47130347 | Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE. |
| Q33892353 | Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis - a prospective cohort study |
| Q36439968 | Parity influences the severity of ACPA-negative early rheumatoid arthritis: a cohort study based on the Swedish EIRA material |
| Q44929035 | Patients with regular physical activity before onset of rheumatoid arthritis present with milder disease. |
| Q60952997 | Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation |
| Q38642378 | Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. |
| Q51740991 | Predicting methotrexate resistance in rheumatoid arthritis patients. |
| Q33747444 | Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms |
| Q27692641 | Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine |
| Q38682209 | Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study |
| Q87339962 | Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis |
| Q37456609 | Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate |
| Q40850003 | Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis |
| Q31041008 | Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden |
| Q42633541 | Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? |
| Q92277447 | Risk Factors and Prevention Strategies for Postoperative Opioid Abuse |
| Q38182346 | Risk estimation in rheumatoid arthritis: from bench to bedside |
| Q36027446 | Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate |
| Q36306270 | Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis |
| Q35792901 | Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial |
| Q36693727 | Smoking Functions as a Negative Regulator of IGF1 and Impairs Adipokine Network in Patients with Rheumatoid Arthritis |
| Q38766413 | Smoking and Air Pollution as Pro-Inflammatory Triggers for the Development of Rheumatoid Arthritis. |
| Q35101727 | Smoking and pulmonary fibrosis: novel insights |
| Q55285482 | Smoking-induced aggravation of experimental arthritis is dependent of aryl hydrocarbon receptor activation in Th17 cells. |
| Q84892324 | Smoking: keeping the joint alight |
| Q30575606 | The Effect of Stopping Smoking on Disease Activity in Rheumatoid Arthritis (RA). Data from BARFOT, a Multicenter Study of Early RA |
| Q27022645 | The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses |
| Q42336552 | The genetics of rheumatoid arthritis: new insights and implications |
| Q35026728 | Three cases of previous smokers with rheumatoid arthritis who did not respond to tumor necrosis factor inhibitors were treated successfully with an anti-interleukin-6 receptor antibody |
| Q44293608 | Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis |
| Q35174817 | Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial |
| Q55379346 | Vapour, gas, dust and fume occupational exposures in male patients with rheumatoid arthritis resident in Cornwall (UK) and their association with rheumatoid factor and anti-cyclic protein antibodies: a retrospective clinical study. |
| Q92325556 | Widespread pain and pain intensity in patients with early rheumatoid arthritis. A cross-sectional comparison between smokers and non-smokers |
| Q56968449 | [S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs] |
Search more.